I. COMMENCED TRADING IN FEBRUARY
Company (Symbol) |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price Per Share/Unit |
Gross(M) |
Net (M) |
Shares Out (M) |
Fully Dil. (M) |
Lead Underwriters |
INITIAL OFFERINGS | |||||||||
Albany Molecular Research Inc.(AMRI)* |
1/5 |
2/3 |
2.5S |
$20.00 |
$50.0 |
$45.5 |
12.5 |
16.1 |
INGB;HQ |
AnorMED Inc**.(TSE:AOM) |
2/8 |
2/25 |
5.0S |
$4.04 |
$20.2 |
$18.2 |
ND |
ND |
NB |
Invitrogen Corp.(IVGN)*** |
12/10; 1/28 |
2/26 |
3.0S |
$15.00 |
$45.0 |
$41.1 |
12.6 |
12.6 |
DLJ;WDR; PJI |
TOTAL: $115.2M | |||||||||
NOTES: | |||||||||
* Albany Molecular Research Inc. had originally filed a prospectus for an initial public offering (IPO) of 2.2M shares priced between $15 and $17 each on 7/9/98. The company postponed the offering in early September due to market conditions, but reactivated it in January 1999, offering the same number of shares at a higher price range. However, it ended up selling 0.3M more shares than planned at $1.00 above the high end of the offering range. | |||||||||
** AnorMED Inc.¿s IPO occurred in Canada. Prices have been converted at an exchange rate of C$1.51/US$1. | |||||||||
*** On 1/28/99, Invitrogen Corp. raised the number of shares to be offered in its IPO to 3.5M from 3M. The company sold 3M shares, while existing stockholders sold 0.5M. | |||||||||
FOLLOW-ON OFFERINGS | |||||||||
PowderJect Pharmaceuticals plc (LSE:PJP; U.K.)* |
2/1 |
2/11 |
8.0S |
$11.056 |
$88.8 |
$85.8 |
72.4 |
ND |
RF |
TOTAL: $88.8M | |||||||||
NOTE: | |||||||||
* PowderJect Pharmaceuticals plc sold 8.03M common sharesnon the London Stock Exchange (LSE) in a placing and open offer on a 1 for 8 basis. Prices have been converted at an exchange rate of £0.606/US$1. |
II. FILED AND PENDING
Company (Symbol) |
Date Filed |
Shares/Units (M) |
Price Range |
SharesOut (M) |
Lead, Other UWs |
Value@ ($M) |
INITIAL OFFERINGS | ||||||
Clontech Laboratories Inc.* |
2/19 |
ND |
ND |
ND |
BTAB; HQ; LB |
$73.6 |
NOTES: | ||||||
* Clontech Laboratories Inc.¿s preliminary prospectus for its initial public offering (IPO) did not state the number of shares being offered nor the price range. It did say, however, that it intends to raise a maximum of $73.6M through the sale of stock being offered by the company and by selling shareholders. | ||||||
FOLLOW-ON OFFERINGS
Company (Symbol) |
Date Filed |
Shares/Units (M) |
Price Range |
SharesOut (M) |
Lead, Other UWs |
Value@ ($M) |
Abgenix Inc. (ABGX) |
1/27 |
3.0S |
------ |
14.6 |
BRS; LB; PGE |
$46.7 |
Cerus Corp. (CERS) |
2/11 |
2.0S |
------ |
11.4 |
MSC; BTAB; SGC |
$51.0 |
ChiRex Inc. (CHRX)* |
2/24 |
2.5 |
------ |
14.4 |
CSFBC; DRW; HQ; LM |
$51.3 |
NOTE: | ||||||
* ChiRex Inc. filed a shelf registration in 1998, which became effective on 12/28/98, covering the future sale of up to $100M in debt securities, preferred stock, depositary shares, warrants and common stock. The shares now being offered are part of that shelf registration. |
III. WITHDRAWN OR POSTPONED
Company (Symbol) |
Date Filed |
Shares/Units(M) |
Price Range |
SharesOut(M) |
Lead, Other UWs |
Value@ ($M) |
Biovector Therapeutics SA(France)* |
2/1 |
5.0S |
$6-$7 |
15.2 |
PAR |
$30 |
Intracel Corp.** |
7/9; 1/25 |
4.0S |
$12-$14 |
15.4 |
DLJ; PJI |
$48 |
Phytera Inc.*** |
10/28;1/14 |
2.5S |
$12-$14 |
8.2 |
SGC; CI; BRS |
$30 |
NOTES: | ||||||
* Biovector Therapeutics SA postponed its initial public offering (IPO) on 2/22/99, citing market conditions. The company had planned to come public on Le Nouveau Marche. | ||||||
*** Phytera Inc. announced 2/12/99 that it had temporarily delayed its IPO. The company intends to file an amended registration statement containing its year-end financial statements for 1998. | ||||||
OTHER NOTES: | ||||||
E = estimated; ND = not disclosed, reported and/or available; S = shares; U = units; W = warrants | ||||||
¿Date filed¿ indicates the date on which the company announced that it had filed a preliminary prospectus with the Securities and Exchange Commission for its offering. It is not necessarily the same date as that which is printed on the preliminary prospectus itself. | ||||||
Underwriters¿ Key: | ||||||
BRS (BancBoston Robertson Stephens Inc.); BTAB (BT Alex. Brown Inc.); CI (Carnegie Inc.); CSFBC (Credit Suisse First Boston Corp.); DLJ (Donaldson, Lufkin & Jenrette Securities Corp.); DRW (Dain Rauscher Wessels); HQ (Hambrecht & Quist LLC); INGB (ING Baring Furman Selz LLC); LB (Lehman Brothers); LM (Legg Mason Wood Walker Inc.); MSC (Morgan Stanley & Co. Inc.); NB (Nesbitt Burns Inc.); PAR (Paribas Capital); PGE (Pacific Growth Equities Inc.); PJI (Piper Jaffray Inc.); RF (Robert Fleming & Co. Ltd.); SGC (SG Cowen Securities Corp.); WDR (Warburg Dillon Read LLC) |